Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company’s strategy and the broader industry trend to shed low-growth segments.
Novartis is currently in the initial phase of assessing a potential sale. Although discussions are underway, there remains uncertainty surrounding the outcome, emphasizing that a deal is not guaranteed, Bloomberg reports.
Advanced Accelerator Applications produces radioactive medicines treating ailments like cancer and is a pioneer in molecular imaging, aiding in the …
